HGWM
NKTR icon

Harvest Group Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Harvest Group Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1
Closed – – 470
2020
Q4 		$0 Buy
+1
New +$258 ﹤0.01% 790
2020
Q1 		– Sell
-7
Closed -$2K – 828
2019
Q4 		$2K Buy
+7
New +$2.03K ﹤0.01% 644

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Harvest Group Wealth Management's NKTR Position: Q1 2021 in Review

Harvest Group Wealth Management sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 1 share.

Harvest Group Wealth Management first reported a position in NKTR in Q4 2019 and held it in 2 quarters. The position peaked at $2K in Q4 2019. 236 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

  • Harvest Group Wealth Management reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Harvest Group Wealth Management sold 1 Nektar Therapeutics share in Q1 2021.
  • Harvest Group Wealth Management first reported a position in Nektar Therapeutics in Q4 2019 and held it in 2 quarters.
  • Harvest Group Wealth Management's Nektar Therapeutics position peaked at $2K in Q4 2019.
  • 236 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on Harvest Group Wealth Management's 13F filing for Q1 2021, filed 4 May 2021.